You are currently browsing the archives for 26 April 2018.
Displaying 1 entry.

Amira submits IND program for AM152 antagonist Amira Pharmaceuticals.

While there are no LPA1 selective antagonists accepted for therapeutic use, there exists a strong scientific rationale for this target to be a novel treatment in a variety of fibrotic illnesses, including scleroderma and idiopathic pulmonary fibrosis.. Amira submits IND program for AM152 antagonist Amira Pharmaceuticals, Inc. Announced today that it provides submitted an Investigational New Drug program to the US Food and Medication Administration for AM152, a novel LPA1 antagonist. We believe the pre-medical data obtained to date for AM152 demonstrate characteristics which warrant additional studies in human beings to determine its potential utility in various fibrotic diseases, stated Isabelle DeArmond, Vice President, Clinical Advancement.